UPDATE: RBC Capital Downgrades Karyopharm Therapeutics (KPTI) to Sector Perform

August 5, 2021 4:05 PM EDT
Get Alerts KPTI Hot Sheet
Price: $6.20 --0%

Rating Summary:
    11 Buy, 3 Hold, 2 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 6 | Down: 11 | New: 18
Trade Now! 
Join SI Premium – FREE
(Updated - August 5, 2021 4:05 PM EDT)

RBC Capital analyst Brian Abrahams downgraded Karyopharm Therapeutics (NASDAQ: KPTI) from Outperform to Sector Perform with a price target of $8.00 (from $17.00).

The analyst comments ": Xpovio uptake has appeared to hit an impasse, and though it is possible we could see earlier-line share gains and better persistence lead to some 2H21 growth, with limited signs of pull-through now several quarters into BOSTON data and label expansion, we believe the challenges of COVID, the competitive dynamics, and seli's profile may remain headwinds to a NT sales inflection. We acknowledge endometrial cancer (4Q21 data) and MF could provide NT and LT optionality, Xpovio may still have a role going forward across different heme/onc paradigms, and the new mgmt team could help reinvigorate adoption. That being said, we see limited encouraging datapoints on which to build confidence in Xpovio's growth potential, and as such now hold off on recommending shares until there is more clarity. Downgrade to SP, tgt to $8."

For an analyst ratings summary and ratings history on Karyopharm Therapeutics click here. For more ratings news on Karyopharm Therapeutics click here.

Shares of Karyopharm Therapeutics closed at $7.82 yesterday.

You May Also Be Interested In

Related Categories

Analyst Comments, Analyst PT Change, Downgrades

Related Entities

RBC Capital